Funding cuts for academia and continuing issues for the pharmaceutical industry are causing considerable stress in life sciences and healthcare research. However, new opportunities are developing to enable industry to access high quality, longitudinal patient and genetic data for collaborative translational medicine studies. So does that mean an end to ‘going it alone’?
In my view – yes.
For pharma and academia, collaboration in translational science shouldn’t be feared. It’s already leading to valuable industry funded partnerships between these groups that will ensure vital clinical trials/translational studies continue to lead to improved disease understanding and treatment. And that means better outcomes for everyone.
Not convinced? Read a full discussion in August’s edition of International Clinical Trials.